Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2008 1
2014 1
2015 5
2016 7
2017 11
2018 16
2019 9
2020 20
2021 26
2022 12
2023 17
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer.
Hsu R, Al-Zubeidy B, Flores D, Nazarian A, Baugh A, Gonzalez E, Castanon S, Xiu J, Kang I, Spicer D, Lenz HJ, Dara L, Ademuyiwa FO, Korn WM, Irshad S, Chan IS, Roussos Torres ET. Hsu R, et al. Among authors: xiu j. Breast Cancer Res Treat. 2024 Apr 20. doi: 10.1007/s10549-024-07295-w. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38643348
Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers.
Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, Lenz HJ, Shields AF, Nabhan C, Oberley M, Seeber A, El-Deiry W. Lou E, et al. Among authors: xiu j. Mol Ther Oncol. 2024 Feb 28;32(1):200786. doi: 10.1016/j.omton.2024.200786. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596288 Free PMC article.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: xiu j. Nat Cancer. 2024 Mar 25. doi: 10.1038/s43018-024-00752-x. Online ahead of print. Nat Cancer. 2024. PMID: 38528112
Sex differences in glioblastoma response to treatment: Impact of MGMT methylation.
Cioffi G, Waite KA, Dmukauskas M, Glantz M, Aulakh S, Nicolaides T, Sengupta S, Xiu J, Barnholtz-Sloan JS. Cioffi G, et al. Among authors: xiu j. Neurooncol Adv. 2024 Mar 1;6(1):vdae031. doi: 10.1093/noajnl/vdae031. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38476929 Free PMC article. No abstract available.
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. Arai H, et al. Among authors: xiu j. Eur J Cancer. 2024 Apr;201:113914. doi: 10.1016/j.ejca.2024.113914. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38359495
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
Khushman MM, Toboni MD, Xiu J, Manne U, Farrell A, Lou E, Shields AF, Philip PA, Salem ME, Abraham J, Spetzler D, Marshall J, Jayachandran P, Hall MJ, Lenz HJ, Sahin IH, Seeber A, Powell MA. Khushman MM, et al. Among authors: xiu j. Clin Cancer Res. 2024 May 1;30(9):1906-1915. doi: 10.1158/1078-0432.CCR-23-3004. Clin Cancer Res. 2024. PMID: 38350001
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, Lopes G, Nieva JJ, Borghaei H, Takebe N, Ma PC, Halmos B, Kwiatkowski DJ, Liu SV, Mamdani H. Naqash AR, et al. Among authors: xiu j. JCO Precis Oncol. 2024 Feb;8:e2300371. doi: 10.1200/PO.23.00371. JCO Precis Oncol. 2024. PMID: 38330261
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM, Demidova EV, Ringenbach S, Faezov B, Andrake M, Gandhi A, Mur P, Viana-Errasti J, Xiu J, Swensen J, Valle L, Dunbrack RL Jr, Hall MJ, Arora S. Shah SM, et al. Among authors: xiu j. Cancer Res Commun. 2024 Jan 26;4(1):213-225. doi: 10.1158/2767-9764.CRC-23-0312. Epub 2024 Jan 8. Cancer Res Commun. 2024. PMID: 38282550 Free PMC article.
125 results